Pfizer (NYSE:PFE) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Key Points

• Royal Bank of Canada raised its Pfizer price target from $25 to $28 but maintained a “sector perform” rating; the new target was about 8.3% below the stock’s then-current price.
• Pfizer reported quarterly earnings of $0.87 per share, above the $0.74 consensus, and revenue of $16.58 billion, also beating estimates; revenue was down 0.4% year over year.
• Analyst sentiment was broadly neutral: MarketBeat reported a consensus “Hold” rating and an average price target of $28.82.

Pfizer (NYSE:PFE - Get Free Report) had its price objective upped by research analysts at Royal Bank Of Canada from $25.00 to $28.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has a "sector perform" rating on the biopharmaceutical company's stock. Royal Bank Of Canada's price objective indicates a potential downside of 8.27% from the stock's current price.

Several other research analysts have also recently weighed in on the stock. HSBC boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a research report on Thursday, September 10th. Weiss Ratings raised shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Scotiabank boosted their target price on shares of Pfizer from $30.00 to $33.00 and gave the company an "outperform" rating in a report on Tuesday, October 6th. BMO Capital Markets dropped their price target on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. Finally, JPMorgan Chase & Co. raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 9th. Five investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $28.82.

Pfizer Price Performance

PFE traded up $0.53 during trading on Wednesday, reaching $30.52. The company's stock had a trading volume of 19,826,121 shares, compared to its average volume of 39,685,324. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a fifty day simple moving average of $28.64 and a two-hundred day simple moving average of $26.84. Pfizer has a 1 year low of $23.62 and a 1 year high of $31.06. The company has a market cap of $173.98 billion, a price-to-earnings ratio of 40.13, a PEG ratio of 2.08 and a beta of 0.31.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.13. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the business earned $0.87 earnings per share. The business's revenue was down .4% compared to the same quarter last year. As a group, analysts anticipate that Pfizer will post 2.94 EPS for the current year.

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently made changes to their positions in the stock. Retirement Wealth Solutions LLC boosted its position in shares of Pfizer by 144.6% during the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 509 shares during the period. Keb Asset Management LLC acquired a new position in Pfizer in the 2nd quarter valued at about $26,000. Field & Main Bank purchased a new stake in Pfizer during the second quarter worth about $27,000. Bullseye Investment Management LLC purchased a new stake in Pfizer during the second quarter worth about $28,000. Finally, Timbuktu Capital Management LLC acquired a new stake in shares of Pfizer during the second quarter worth about $29,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer raised its 2026 revenue outlook to $62 billion–$64 billion and adjusted EPS guidance to $2.95–$3.05, following third-quarter results that topped analyst estimates. Pfizer Q3 earnings highlights
• Positive Sentiment: Growth beyond COVID is helping support the outlook: launched and acquired products grew 32% operationally in Q3, while non-COVID products overall grew 7%. Eliquis and oncology medicines were among the growth drivers. Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Investors also have potential longer-term upside to watch in Pfizer’s renewed obesity-drug push, which CEO Albert Bourla says could draw on the company’s experience building successful medicines. The opportunity is not yet established commercial growth. Pfizer CEO Bourla on obesity market
• Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan as permanent CFO. The appointment provides leadership continuity, but no immediate financial impact was reported. Pfizer appoints Cecile Guegan as CFO
• Negative Sentiment: Q3 revenue was essentially flat year over year, as falling COVID vaccine and treatment sales—including declines in Comirnaty and Paxlovid—offset growth elsewhere. This underscores Pfizer’s ongoing need to replace pandemic-era revenue. Pfizer Q3 revenue and product growth

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.